Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation

Nature Communications

Volumn 5, Issue , 2014, Pages

  Obata, Yuuki ^a   Toyoshima, Shota ^a   Wakamatsu, Ei ^a   Suzuki, Shunichi ^a   Ogawa, Shuhei ^a   Esumi, Hiroyasu ^a,b   Abe, Ryo ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CLATHRIN; KIT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; STAT5 PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

BLOOD SYSTEM DISORDER; CANCER; CELL ORGANELLE; ENZYME ACTIVITY; MEMBRANE; MUTATION; RODENT;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; ENDOCYTOSIS; ENDOLYSOSOME; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; INTERNALIZATION; INTRACELLULAR SPACE; LEUKEMIA CELL; LYSOSOME; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; OUTER MEMBRANE; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UBIQUITINATION;

MUS; RATTUS;

EID: 84923322628     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6715     Document Type: Article

References (70)

1. Besmer, P. et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320, 415-421 (1986).
2. Yarden, Y. et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6, 3341-3351 (1987).
3. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
4. Kitamura, Y. & Hirota, S. Kit as a human oncogenic tyrosine kinase. Cell Mol. Life Sci. 61, 2924-2931 (2004).
5. Rönnstrand, L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol. Life Sci. 61, 2535-2548 (2004).
6. Roskoski, R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun. 338, 1307-1315 (2005).
7. Blume-Jensen, P., Janknecht, R. & Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779-782 (1998).
8. Timokhina, I., Kissel, H., Stella, G. & Besmer, P. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 17, 6250-6262 (1998).
9. Broudy et al. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94, 1979-1986 (1999).
10. Ma, P. et al. Balanced interactions between Lyn, the p85α regulatory subunit of class IA phosphatidylinositol-3-kinase, and SHIP are essential for mast cell growth and maturation. Mol. Cell Biol. 31, 4052-4062 (2011).
11. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
12. Furitsu, T. et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligandindependent activation of c-kit product. J. Clin. Invest. 92, 1736-1744 (1993).
13. Boissan, M., Feger, F., Guillosson, J. J. & Arock, M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J. Leukoc. Biol. 67, 135-148 (2000).
14. Lasota, J. & Miettinen, M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53, 245-266 (2008).
15. Chian, R. et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 98, 1365-1373 (2001).
16. Aichberger, K. J. et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114, 5342-5351 (2009).
17. Jahn, T., Leifheit, E., Gooch, S., Sindhu, S. & Weinberg, K. Lipid rafts are required for Kit survival and proliferation signals. Blood 110, 1739-1747 (2007).
18. Gordon, P. M. & Fisher, D. E. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J. Biol. Chem. 285, 14109-14114 (2010).
19. Ning, Z. Q., Li, J. & Arceci, R. J. Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokineindependent survival and proliferation in human leukemia cells. Blood 97, 3559-3567 (2001).
20. Baumgartner, C. et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am. J. Pathol. 175, 2416-2429 (2009).
21. Chaix, A. et al. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J. Biol. Chem. 286, 5956-5966 (2009).
22. Ronchetti, D. et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20, 3553-3562 (2003).
23. Chung, B. M. et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC. Cell Biol. 10, 84 (2009).
24. Joffre, C. et al. A direct role for Met endocytosis in tumorigenesis. Nat. Cell Biol. 13, 827-837 (2011).
25. Williams, A. B. et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 120, 3069-3079 (2012).
26. Choudhary, C. et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326-339 (2009).
27. Toffalini, F. & Demoulin, J. B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 116, 2429-2437 (2010).
28. Mitsui, H. et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl Acad. Sci. USA 90, 735-739 (1993).
29. Growney, J. D. et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106, 721-724 (2005).
30. Xiang, Z., Kreisel, F., Cain, J., Colson, A. L. & Tomasson, M. H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell Biol. 27, 267-282 (2007).
31. Tabone-Eglinger, S. et al. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin. Cancer Res. 14, 12285-12294 (2008).
32. Bougherara, H. et al. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol. Cancer Res. 7, 1525-1533 (2009).
33. Jahn, T. et al. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 21, 4508-4520 (2002).
34. Kon, S. et al. Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia. J. Clin. Invest. 123, 1123-1137 (2013).
35. Mercer, J. & Helenius, A. Virus entry by macropinocytosis. Nat. Cell Biol. 11, 510-520 (2009).
36. Naal, R. M., Holowka, E. P., Baird, B. & Holowka, D. Antigen-stimulated trafficking from the recycling compartment to the plasma membrane in RBL mast cells. Traffic 4, 190-200 (2003).
37. Sigismund, S. et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 15, 209-219 (2008).
38. Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F. & Wrana, J. L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 5, 410-421 (2003).
39. Sigismund, S. et al. Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol. Rev. 92, 273-366 (2012).
40. Heuser, J. E. & Anderson, R. G. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J. Cell Biol. 108, 389-400 (1989).
41. von Kleist, L. et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146, 471-484 (2011).
42. Orlandi, P. A. & Fishman, P. H. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 141, 905-915 (1998).
43. Acconcia, F., Sigismund, S. & Polo, S. Ubiquitin in trafficking: The network at work. Exp. Cell Res. 315, 1610-1618 (2009).
44. Hayer, A. et al. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J. Cell Biol. 191, 615-629 (2010).
45. Yee, N. S., Hsiau, C. W., Serve, H., Vosseller, K. & Besmer, P. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J. Biol. Chem. 269, 31991-31998 (1994).
46. Stuffers, S., Wegner, S. C., Stenmark, H. & Brech, A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic 10, 925-937 (2009).
47. Mali, R. S. et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20, 357-369 (2011).
48. Joly, M., Kazlauskas, A., Fay, F. S. & Corvera, S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites. Science 263, 684-687 (1994).
49. Er, E. E., Mendoza, M. C., Mackey, A. M., Rameh, L. E. & Blenis, J. AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. Sci. Signal 6, ra45 (2013).
50. Ménard, L., Parker, P. J. & Kermorgant, S. Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways. Nat. Commun. 5, 3907 (2014).
51. Wang, Y., Pennock, S. D., Chen, X., Kazlauskas, A. & Wang, Z. Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J. Biol. Chem. 279, 8038-8046 (2004).
52. Sun, Y., Hedman, A. C., Tan, X., Schill, N. J. & Anderson, R. A. Endosomal type Ig PIP 5-kinase controls EGF receptor lysosomal sorting. Dev. Cell 25, 144-155 (2013).
53. Kim, M. S., Rådinger, M. & Gilfillan, A. M. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 29, 493-501 (2008).
54. Várnai, P. & Balla, T. Visualization of phosphoinositides that bind pleckstrin homology domains: calcium- and agonist-induced dynamic changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools. J. Cell Biol. 143, 501-510 (1998).
55. Clague, M. J., Urbé, S., Aniento, F. & Gruenberg, J. Vacuolar ATPase activity is required for endosomal carrier vesicle formation. J. Biol. Chem. 269, 21-24 (1994).
56. Griffiths, G., Quinn, P. & Warren, G. Dissection of the Golgi complex. I. Monensin inhibits the transport of viral membrane proteins from medial to trans Golgi cisternae in baby hamster kidney cells infected with Semliki Forest virus. J. Cell Biol. 96, 835-850 (1983).
57. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019-1049 (2004).
58. Klausner, R. D., Donaldson, J. G. & Lippincott-Schwartz, J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116, 1071-1080 (1992).
59. Schmidt-Arras, D. et al. Oncogenic deletion mutants of gp130 signal from intracellular compartments. J. Cell Sci. 127, 341-353 (2014).
60. Kazi, J. U., Agarwal, S., Sun, J., Bracco, E. & Rönnstrand, L. Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. J. Cell Sci. 127, 653-662 (2014).
61. Cremona, O. et al. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99, 179-188 (1999).
62. Shin, H. W. et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170, 607-618 (2005).
63. Rong, Y. et al. Clathrin and phosphatidylinositol-4,5-bisphosphate regulate autophagic lysosome reformation. Nat. Cell Biol. 14, 924-934 (2012).
64. Sridhar, S. et al. The lipid kinase PI4KIIIβ preserves lysosomal identity. EMBO J. 32, 324-339 (2013).
65. Bandi et al. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 114, 4197-4208 (2009).
66. Zeng, S., Xu, Z., Lipkowitz, S. & Longley, J. B. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105, 226-232 (2005).
67. Zermati, Y. et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22, 660-664 (2003).
68. Bauer, S., Duensing, A., Demetri, G. D. & Fletcher, J. A. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26, 7560-7568 (2007).
69. Edris et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc. Natl Acad. Sci. USA 110, 3501-3506 (2013).
70. Scaltriti et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803-814 (2009).